The present invention provides a pharmaceutical composition comprising Losartan or salts thereof in admixture with pharmaceutically acceptable excipients and a method for the preparation of said composition wherein the composition is prepared by dry granulation method.

The present invention provides a pharmaceutical composition comprising Topiramate or salt thereof in admixture with pharmaceutically acceptable excipients and a method for the preparation of said composition wherein the composition is prepared by wet granulation method.

The present invention provides a process for a preparation of clopidogrel hydrochloride from clopidogrel chiral auxiliary, wherein the said process comprises of, a) Converting salt of clopidogrel chiral auxiliary to clopidogrel base in organic solvent b) to the reaction mixture of step a) added alcoholic hydrochlori...

The present invention provides an efficient process for the preparation and purification of nizatidine. A process for the preparation of nizatidine of formula I, wherein the said process comprises of, a) reacting 2-(Dimethylaminomethyl)-4-thiazole methanol with cysteamine hydrochloride, b) treating reaction mass of...

The present invention provides a stable solid oral dosage formulation comprising trandolapril or salt thereof in admixture with pharmaceutically acceptable excipients, wherein the said formulation is prepared by direct compression method.

The present invention provides an injectable pharmaceutical composition of docetaxel or salts thereof, comprising a stock solution and a diluent solution, wherein stock solution comprises docetaxel or salts thereof along with pharmaceutically acceptable excipients and 5 to 50% of ethanol and the diluent solution "es...

The present invention relates to a process for preparation of octreotide acetate, wherein the said process comprises of a) charging octreotide or salt thereof wherein the salt is other than acetate, over reparative chromatography column, b) eluting the column with 0.1 to 4% ammonium acetate and 0.1-2% acetic acid, ...

A new oral pharmaceutical dosage form comprising an alkaline core structure that is layered with a proton pump inhibitor which is interspersed between layers of alkaline material. An enteric coating layer is formed by in situ reaction between polymethacrylate weak anion and strong base cation and is applied on the d...

The preentent invention relates to pharmaceuitical composition comprising a swellable matrix comprising hydroxyethyl cellulose. The matrix is surrrounded by a water dispersible membrane comprising a low viscosity hydroxyethylcellulose substituded with hydroxyethoxy groups; and hydroxyalkyl cellulose optionally subst...

A process for preparation of compound of Formula (I) is disclosed.

A process for preparation of compound of Formula (I) is disclosed.

Substituted biaryl oxazolidinones compounds of formula (I), method of their preparation and pharmaceutical compositions containing these compounds are provided.

The present application relates to a process for the preparation of chloro derivative of pantoprazole of Formula II or pharmaceutical acceptable salt thereof Formula II wherein –Cl group may be present at C4, C6, or C7 position.

The present invention provides a process for the preparation of Dronedarone. The process includes conversion of (i) 2-n-butyl-3-(4-hydroxy benzoyl)-5-nitro benzofuran to 2-n-butyl-3-[4-(3-di-n-butylamino-propoxy) benzoyl]-5-nitro benzofuran mono oxalate by reaction with 1-chloro-3-di-n-butylamino propane and oxalic ...

The present application relates to a process for the preparation of analogue of aripiprazole of Formula II or pharmaceutical acceptable salt thereof which are present as impurities in the aripiprazole and use of theses impurities as reference marker to quantify the presence of these analogue in aripirazole. Form...

There is provided an improved process for preparing microparticles. More particularly  a process is provided for preparing microparticles having a selected release profile for release of drug contained in the microparticles. By subjecting the emulsion to multiple washing in a single quench or extraction tank followe...

The present invention relates to a process for the purification of Ziprasidone or its pharmaceutically acceptable salt free from its impurities  for example  oxindole  comprises suspending or crystallizing Ziprasidone crude from a mixture of dimethyl sulfoxide and excess of tetrahydrofuran.

The present invention relates to cyclo dehydration of 2-Hydroxy-N-(2-hydroxy-benzoyl)-benzamide in the presence of bronsted acid/lewis acid catalyst at a reduced temperature of 1200C -1300C to yield 2-(2-hydroxyphenyl) Benz[e] [1  3] oxazin-4-one.

The invention relates to the pharmaceutical composition comprising microparticles having improved flow characteristics. There is provided a process of preparing such microparticles composition.

Abstract The present invention provides an oral pharmaceutical composition comprising one or more units of dabigatran etexilate or salts thereof and one or more units of organic acid. By providing separate one or more units of dabigatran etexilate or salts thereof and one or more units of organic acid it is possi...

The present invention relates to an improved process for the preparation of (2S,3R)-3-(2,5-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4-triazol-1-yl)butanenitrile. In a particular aspect of the present invention relates to one pot process for the preparation of hydroxyl-nitrile intermediate, which is a key interme...

The present invention provides a process for the preparation of 7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)quinolin-2(1H)-one, compound of formula II or pharmaceutical acceptable salts thereof, which may present in aripiprazole as an impurity. Formula II

The present invention provides a process for the preparation of Sitagliptin fumarate adduct or salt thereof. In particular aspect of present invention provides a Lithium salt of Sitagliptin fumarate adduct. In further aspect of present provides the use of a Sitagliptin fumarate adduct or salt thereof as reference ma...

The present invention relates to solid oral modified-release composition comprising budesonide or salts thereof. In particular, the present invention relates to solid oral modified-release composition comprising matrix of budesonide or salts thereof with one or more amphiphilic excipients and one or more hydrophilic...

A stabilized pharmaceutical composition comprising fluvastatin or salts thereof and a pharmaceutically acceptable polymer in admixture with pharmaceutically acceptable excipients, wherein the said composition comprises fluvastatin coated with the said pharmaceutically acceptable polymer.

The present invention relates to the novel aryl boronic acids of the general formula-I. The invention also relates to processes for the preparation of compounds of the present invention. Wherein, R1 is selected from the group of hydrogen, C1-C6 alkyl, halogen and CN; R2 is halogen or OR5, wherein R5 is selected from...

The present invention provides a process for the preparation of pure iodinated X- ray contrast agents. More particularly this invention provides a process for the preparation of pure loversol. Chemically, ioversol is N,N'-bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl)-glycolamido]-2,4,6-triiodo isophthalamide havin...

A pharmaceutical composition comprising unmicronized fenofibrate or salt thereof in admixture with wetting agent and one or more pharmaceutically acceptable excipients, wherein the said admixture is not comicronized before processing.

The present invention provides a process for preparation of ioversol wherein the said process comprising, a) reacting 5-amino-N,N’-bis(2,3-dihydropropyl)-2,4,6-trilodoiso phthalamide with chloroacetyl chloride in polar aprotic solvent b) converting the product of step a) to ioversol.

A sustained release formulation, which comprises of : first layer comprising alfuzosin or salt thereof and at least one hydrophilic rate controlling polymer, second layer comprising alfuzosin or salt thereof and at least one hydrophilic rate controlling polymer, an optional third layer which comprises of hydrophili...

A sustained release formulation, which comprises of (a) first layer comprising alfuzosin or salt thereof and less than 5% of at least one hydrophilic rate controlling polymer. (b) Second layer comprising alfuzosin or salt thereof and 0.5 to 95% of at least one hydrophilic rate controlling polymer, (c) An optiona...

A pharmaceutical controlled-release dosage form adapted to release zolpidem or a salt thereof over a predetermined time period, according to a biphasic in vitro profile of dissolution when measured in a type II dissolution apparatus according to the U.S. Pharmacopoeia in 0.01M hydrochloric acid buffer at 37°C, wher...

A process for preparation of anhydrous azithromycin wherein the said process comprises of a)removing the moisture from a solution/suspension of azithromycin, b)stirring the resultant mass in a water miscible solvent, c)optionally recovering the solvent by distillation, d)isolating anhydrous azithromycin from rea...

A stable solid oral dosage formulation comprising of ramipril and its salt thereof, wherein ramipril is mixed with at least one pharmaceutically accepted excipients, which is pre-coated and a lubricant.

A pharmaceutical composition comprising an intra-granular and an extra-granular phase wherein the intra-granular phase comprises of gatifloxacin or salt, solvate or hydrate thereof without any pharmaceutically acceptable excipient and the extra-granular phase comprises of at least one pharmaceutically acceptable exc...

A liquid dosage form for ophthalmic, otic or nasal administration which comprises of nadifloxacin or salt thereof in a concentration of 0.01% to 1% by weight and suitable pharmaceutically acceptable vehicle therefor.

In the present invention there is provided a process for the preparation of amlodipine besylate, wherein the said process includes the step of: a) reacting amlodipine base with benzene sulphonic acid in an alcohol, b) isolating the crude amlodipine besylate from the reaction mass thereof.

The present invention provides pharmaceutical composition of fenofibrate or salts thereof comprising micronized fenofibrate, one or more surfactants other than dioctylsulfosuccinate along with pharmaceutically acceptable excipients. The present invention also provides a process of preparing pharmaceutical compositio...

The present invention provides pharmaceutical composition comprising non-micronized fenofibrate or salts thereof, and one or more vehicle optionally with one or more pharmaceutically acceptable excipients. The present invention also provides a process of preparing such pharmaceutical compositions. ...

There is provided a process for preparation of Pramipexole or a salt thereof comprising: (a) reacting 5-(-)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with w-propanal in a mixture of water and at least one polar organic solvent, (b) treating reaction mass obtained in step (a) with a reducing agent, (c) isolating...

The invention provides substituted [2-(4-diphenylmethyl piperazin-1-yl)-ethoxy] acetic acid derivatives and salts thereof. The invention further provides a pharmaceutical composition comprising substituted [2-(4-diphenylmethyl)-piperazin-1-yl)-ethoxy] acetic acid derivatives and salts thereof.

The invention relates to crystalline S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt tetrahydrate, a process for its preparation and pharmaceutical formulations incorporating it as the active ingredient for use in treating microbial ...

The present invention provides stabilized pharmaceutical composition comprising bupropion or salt thereof and stabilizing agent along with other pharmaceutically acceptable excipients wherein the stabilizing agent is capable of maintaining a pH of less than 6 around bupropion particles.

The present invention relates to a process for preparation of venlafaxine or salt thereof wherein the said process comprises of a) reducing cyano intermediate of Formula 2 with Raney Nickel KALCAT-8030 in presence of an ammoniacal alkanol to get the amine intermediate of Formula 4, b) N-methylating the amine interme...

The present invention provides a process of preparation of escitalopram oxalate Form-I, wherein the said process comprises of crystallizing escitalopram from aqueous isopropanol and isolating Form I of escitalopram from mixture thereof.

The present invention provides an immediate release pharmaceutical composition of fenofibrate comprising an inert core with at least one layer containing fenofibrate in non-micronized form in admixture with pharmaceutically acceptable excipients and optionally one or more layers.

The present invention provides an improved process for the preparation of nicardipine or salt thereof. Nicardipine hydrochloride of formula I is chemically known as 2-(benzyl-methyl amino) ethylmethyl-1, 4-dihydro - 2, 6-dimethyl-4-(m-nitrophenyl) - 3, 5-pyridine dicarboxylate monohydrochloride. Nicardipine hydrochl...

The present invention provides a process for preparing pharmaceutical composition comprising adsorbate of fenofibrate or pharmaceutically acceptable salt thereof and optionally one or more pharmaceutically acceptable excipients. Fenofibrate is a lipid-regulating agent. The empirical formula is C20H21O4C1 and the mol...

The present invention provides stabilized pharmaceutical composition comprising bupropion or salt thereof and effective stabilizing amount of potassium hydrogen tartrate along with other pharmaceutically acceptable excipients wherein potassium hydrogen tartrate is capable of maintaining a pH of less than 6 around bu...

A single step process for the preparation and purification of duloxetine hydrochloride. The process comprising, (a) combining duloxetine base with suitable organic solvent; (b) treating the solution of step (a) with dry hydrogen chloride; (c) washing the solid mass of step (b) with organic solvent; (d) isolating dul...

The present invention relates to a stabilized pharmaceutical composition comprising fluvastatin or salts thereof, and a mixture of glycine or salts thereof and calcium carbonate along with pharmaceutically acceptable excipients wherein the mixture of glycine or salts thereof and calcium carbonate is present in an am...

The present invention provides a pharmaceutical composition of fenofibrate or pharmaceutically acceptable salts thereof comprising fenofibrate adsorbed on a pharmaceutically acceptable adsorbent wherein the said adsorbent is pregelatinized starch.

The present invention provides novel polymorphic form 'W-lll' of azithromycin. More particularly the present invention provides novel anhydrous polymorphic form 'W-lll. N/-methyl-11-aza-10-deoxo-10-dihydroerythroimycin A, known by its generic name Azithromycin of Formula I, is a broad-spectrum semi-synthetic macroli...

The present invention provides a pharmaceutical composition of losartan or pharmaceutically acceptable salts thereof and hydrochlorothiazide comprising losartan particles, wherein atleast 90% of the losartan particles have particle size between 30 and 100m and the said composition is prepared by direct compression ...

The present invention provides novel polymorphic form 'W-l' of anhydrous azithromycin. following specification particularly The describes the invention and the manner in which it is to be performed.

The present invention provides novel polymorphic form 'W-VI' of anhydrous crystalline azithromycin. N/-methyl-11-aza-10-deoxo-10-dihydroerythromycin A, known by its generic name Azithromycin of Formula I, is a broad-spectrum semi-synthetic macrolide antibiotic compound belonging to the erythromycin A family. ...

The present invention provides a process for converting crystalline azithromycin to anhydrous amorphous azithromycin. A/-methyl-11-aza-10-deoxo-10-dihydroerythromycin A, known by its generic name Azithromycin of Formula I, is a broad-spectrum semi-synthetic macrolide antibiotic compound belonging to the erythromycin...

The present invention relates to (2-{4-[4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid carboxymethyl ester.

A process for preparation of iohexol comprises the steps of, reacting 5-acetamido-N.N'-bis (2,3-dihydroxypropyl)-2,4,6-triiodoisophthalmide with a propylating agent, in presence of 2-ethoxyethanol.

The present invention relates to a process for preparation of Cys)Acm)-Phe-OMe or salt thereof wherein the said process comprises of a) treating t-BOC-Cys(Acm)-Phe-OMe or salt thereof with less than 10 moles of trifluoroacetic acid, b) removing excess trifluoroacetic acid, c) isolating Cys(Acm)-Phe-OMe or salt there...

The present invention relates to an efficient process for the preparation of valacyclovir or salt thereof. Valacyclovir is chemically, L-valyl ester of acyclovir designated as 2-[(2-amino-l,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valyl ester. It is commercially available in form of its hydrochloride salt (Form...

The present invention provides an aqueous liquid pharmaceutical composition comprising gatifloxacin or pharmaceutically acceptable salt thereof. Gatifloxacin is a synthetic broad-spectrum 8-methoxyfluoroquinolone antibacterial agent. Chemically, gatifloxacin is (±)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-m...

The present invention provides an aqueous topical ophthalmic composition comprising 0.3% of ketorolac tromethamine and 1 to 1.5% hydroxypropyl-β-cyclodextrin along with a suitable carrier.

The present invention relates to an efficient process for the preparation of Fluvastatin sodium. Fluvastatin is [R*, S*-(E)]-(±)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H –indol-2-yl]-3,5-dihydroxy-6-heptenoic acid of Formula I. Fluvastatin, is commercially available as Lescol® Capsules and extended release Tablets...

The present invention provides an aqueous liquid pharmaceutical composition, which comprises gatifloxacin or its pharmaceutically acceptable salt with HP-β-CD and polyvinyl alcohol along with other pharmaceutically acceptable excipients.

The present invention relates to a process for preparation of fluvastatin or salt thereof wherein the said process comprises of a) reacting fluvaldehyde of Formula VI, with alkyl acetoacetate of Formula VII, wherein R is as mentioned above in presence of sodium hydride and n-butyl lithium, b) adjusting the pH of rea...

The present invention relates to a process for preparation of trifluoroacetate salt of 8P-OL, wherein the said process comprises of a) coupling of t-BOC-6P-OH and Cys(Acm)-Thr-OL in a suitable organic solvent, b) removing the t-BOC protection from the product t-BOC-8P-OL using trifluoroacetic acid, c) extracting the...

The present invention relates to a process for preparation of R1-(D)Phe-Cys(Acm)-Phe-OH, wherein R1is amino or suitable amino protecting group used in peptide chemistry, wherein the said process comprises of a) hydrolyzing R1-(D)Phe-Cys(Acm)-Phe-OMe in presence of methanol and lithium hydroxide, b) acidifying the re...

The present invention relates to a process for preparation of Fluvastatin or salt thereof wherein the said process comprises of a. reducing β-ketoester of Formula II wherein R is C1-6 alkyl with a suitable reducing agent to get dihydroxy intermediate of Formula IV wherein R is as described above, b. purifying the di...

The present invention relates to a process for preparation of L-Thr-OMe wherein the side process comprises of a) treating L-Thr-OH with methanol and thionyl chloride at a temperature above 45°C, b) removing excess thionyl chloride from the reaction mass, c) isolating L-Thr-OMe from the reaction mass thereof. ...

The present invention provides an aqueous liquid pharmaceutical composition, which comprises Gatifloxacin or its pharmaceutically acceptable salt and polyvinyl alcohol along with other pharmaceutical acceptable excipients.

The present invention provides ophthalmic composition comprising timolol or salt thereof. Timolol is a non-selective beta-adrenergic receptor blocking agent which is chemically (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol. It is commercially available in the form of its maleate salt...

The present invention provides an improved process for the preparation of amlodipine besylate. The present invention relates to an improved process for the preparation of anhydrous amlodipine besylate.

The present invention provides a single step process for preparation of 2,6-diamino- 4,5,6,7-tetrahydrobenzathiazole intermediate useful in preparation of pramipexole and salt thereof.

The present invention provides a process for the preparation of clopidogrel and salts thereof. Further it relates to process for recycling the (R) enantiomer left in the mother liquor, via racemization and resolving the desired enantiomers from the reaction mass.

The present invention provides a facile process for purification of azithromycin. Further the present invention provides a facile process for the purification of azithromycin from "impurity-O".

The present invention relates a process for the preparation of (-) pramipexole or salt thereof wherein the said process comprises of, a) reacting the compounds of Formula II with bromine to get compound of Formula III which is optionally isolated, b) cyclizing the compound of Formula III with thiourea to get compo...

The present invention provides a process for the preparation of (-) pramipexole or salt thereof wherein the said process comprises of, a) cyclizing the compound of Formula II with bromine and thiourea to obtain compound of Formula IV b) reducing the compound of Formula IV with a reducing agent to obtain pramipexole ...

An improved process for preparation of crystalline cefdinir wherein the said process comprises of a) Treating a solution of O-Acetyl HATA of formula II in a suitable solvent with triethylamine, b) isolating O-Acetyl HATA TEA salt of formula III from the reaction mixture obtained thereof, c) converting O-Acetyl HATA ...

The present invention relates to a process for preparation of Form 1 of cefdinir wherein the said process comprises of : dissolving cefdinir or salt thereof in first organic solvent; adding a second organic solvent characterized by the fact that cefdinir is insoluble, slighly soluble or practically insoluble in the ...

The present invention provides a pharmaceutical composition comprising benazepril or pharmaceutically acceptable salt thereof in combination with amlodipine or pharmaceutically acceptable salt thereof wherein atleast 0.5 - 30% of benazepril is not physically separated from amlodipine or pharmaceutically acceptable s...

The present invention provides for an efficient process for the preparation of racemic epinephrine from the starting material 3,4-dihydroxy phenacylchloride. The present invention provides a process for the preparation of the 3",4"-dihydroxy-2-N-benzyl-N-methylamino acetophenone, an intermediate for the preparation ...

The present invention relates to a process for the preparation of Fluvastatin intermediate. More over it related to cyclization process for 3-(4"-fluorophenyl)-1-(1"-methylethyl) indole intermediate using hydrated zinc chloride having moisture content more than 1% in presence of an alcoholic solvent. ...

The present invention provides a process for the preparation of nicardipine or salt thereof. More particularly it relates to a process for the preparation of nicardipine, using 2,6-dimethyl-5-methoxycarbonyl-4-(3-nitrophenyl)-1,4-dihydropyridine -3-carboxylic acid intermediate and thionyl chloride as halogenating ag...

The present invention provides oral composition  of vancomycin or pharmaceutically acceptable salts thereof, in the form of hard gelatin capsule. The invention further provides a novel process for the preparation of said composition.

The present invention provides a pharmaceutical composition comprising quetiapine or salt thereof and an insoluble binder in admixture with filler, disintegrant, lubricant and optionally other pharmaceutically acceptable carrier.

The present invention provides a pharmaceutical composition comprises a combination of 300 mg of acetaminophen, 250 mg of chlorzoxazone and 30 mg of codeine phosphate, wherein codeine phosphate is present as extended release component along with suitable pharmaceutically acceptable excipient.

The present invention provides a solid pharmaceutical dosage form for oral administration comprising: a) an immediate release layer comprising glimepiride; and b) an extended release core comprising metformin or pharmaceutically acceptable salt thereof; wherein the glimepiride is present in the form of complex wit...

The present invention provides a pharmaceutical composition comprises a combination of 325 mg of acetaminophen and 50 mg of dextropropoxyphene napsylate and 50 mg diclofenac potassium, as active ingredients and pharmaceutically acceptable excipients, wherein the diclofenac potassium is present as immediate release f...

The present invention relates to a process for the preparation of pramipexole or salt thereof wherein the said process comprises of, alkylating the compound of Formula X with a propylating agent to obtain pramipexole or salt thereof.

The present invention provides a pharmaceutical composition which comprises of clopidogrel or salt thereof and PEG (Polyethylene Glycol) along with other pharmaceutically acceptable excipients, which comprises of lubricants, selected from group of mineral oils, vegetable oils and glyceryl esters of fatty acids. Gran...

The present invention provides a solid dosage form for oral administration comprising: a) a controlled release core comprising metformin or pharmaceutically acceptable salt thereof along with pharmaceutically acceptable excipients; b) an immediate release layer comprising pioglitazone or pharmaceutically acceptable ...

The present invention provides a pharmaceutical dosage form for oral administration comprising combination of acetaminophen, propoxyphene or pharmaceutically acceptable salt thereof, diclofenac or pharmaceutically acceptable salt thereof and proton pump inhibitor or one of its single enantiomers or salt thereof alon...

The present invention provides a pharmaceutical composition of fenofibrate or salt thereof comprising non-micronized fenofibrate, polyethylene glycol or derivative thereof and one or more pharmaceutically acceptable sugar wherein the said composition is prepared by melt granulation. The present invention also provid...

The present invention relates to improved process for [(2,6-dimethylpheny)-aminocarbonylmethy]chloride, as a ranolazine intermediate.

The present invention relates to a process for purification of [(2,6-dimethylphenyl) aminocarbonylmethyl]chloride, as a ranolazine intermediate.

The present invention provides a pharmaceutical composition comprising irbesartan or salts thereof in solid dispersion with one or more pharmaceutically acceptable dispersing agents optionally along with other pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of such...

The present invention relates to improved process for 1-[(2,6-dimethylphenyl) aminocarbonylmethyl]piperazine intermediate.

The present invention relates to a process for ranolazine and salts thereof. more particularly it relates to a process of coupling of 1-(2-methoxyphenoxy)2,3-epoxypropane with 4-[(2,6-dimethylphenyl)aminocarbonlmethyl]piperazine using a single organic solvent.

The present invention provides a pharmaceutical composition comprising spheroid cores of fenofibrate or salts thereof and one or more spheronizing aid wherein the said composition is prepared by extrusion spheronization.

The present invention provides a pharmaceutical composition of fenofibrate or salts thereof comprising fenofibrate and pharmaceutically acceptable adsorbent wherein the said adsorbent is alternately coated with fenofibrate and one or more surfactants.

The present invention provides a pharmaceutical composition of fenofibrate or pharmaceutically acceptable salts thereof comprising fenofibrate adsorbed on a pharmaceutically acceptable adsorbent wherein the said adsorbent is pregelatinized starch. The present invention also provides a process of preparing the said c...

A pharmaceutical composition of fenofibrate or salts thereof comprising non-micronized fenofibrate, cyclodextrin or derivative thereof and pharmaceutically acceptable carrier wherein the said composition is prepared by (a) complexing a portion of total non-micronized fenofibrate with cyclodextrin or derivative there...

The present invention provides a pharmaceutical composition of fenofibrate or salts thereof comprising fenofibrate, pharmaceutically acceptable adsorbent and polyethylene glycol wherein the said adsorbent and polyethylene glycol or derivative thereof is alternately coated with fenofibrate and surfactant. The present...

The present invention provides to a pharmaceutical composition comprising a centrally acting opioid analgesic agent, an antipyretic agent, and a peripherally acting non-opioid analgesic agent. The compositions of the present invention provide improved analgesia when compared to the individual agents taken alone o...

The present invention relates to stable solutions suitable for ophthalmic, otic, or nasal administration that include a fluoroquinolone antibiotic or salts thereof and amino acid, optionally in combination with one or more drugs.

The present invention provides a stabilized injectable pharmaceutical composition of carboplatin or salts thereof, which comprises of carboplatin or salts thereof dissolved in a suitable pharmaceutically acceptable vehicle along with purged oxygen wherein purged oxygen imparts better stability and significant reduct...

A process for preparation of venlafaxine or salt thereof wherein the said process comprises of, a) providing a solution of the cyno intermediate of formula IV in a high capacity solvent, (b) combining the above solution with a metal hydrogenation catalyst (c) exposing the combination of solution of step (b) to hydro...

The present invention provides a process for preparation of (S)-repaglinide wherein the said process comprises of, a) reacting 3-ethoxy-4-ethoxy carbonyl phenyl acetic acid with halogenating agent in a solvent comprising of halogenated hydrocarbon to get corresponding acid halide of formula III, b) reacting the comp...

A process for purification of adenosine wherein the said process comprises of, a) adding base to suspension or solution of adenosine b) heating the resultant mixture, c) isolating the adenosine from reaction mass thereof.

The present invention provides an ophthalmic composition comprising therapeutically effective amount of brimonidine or salt thereof wherein brimonidine or salt thereof is present in admixture with cyclodextrin or derivative thereof along with ophthalmically acceptable carriers.

The present invention provides an extended release dosage form of metoprolol or salt thereof comprising an inert core coated with a solution or suspension of metoprolol or salt thereof in admixture with pharmaceutically acceptable excipient which is further coated with one or more release-controlling layer(s) wherei...

The present invention provides an ophthalmic composition comprising carboxymethyl cellulose or salt thereof along with ophthalmically acceptable carriers wherein the ophthalmic composition comprises phenylmercuric nitrate as a preservative.

A present invention provides a process for the preparation of nitroether intermediate of formula II useful in preparation of pioglitazone or salt thereof, wherein the said process comprises of a) reacting 5-ethyl-2-pyridyl ethanol (HEEP) with 4-fluoronitrobenzene (4-FNB) using organic solvent mixture in presence of ...

The present invention provides ophthalmic composition comprising dorzolamide or salt or enantiomers or diastereomers or mixtures thereof and timolol or an ophthalmically acceptable salt thereof along with ophthalmically acceptable carriers.

The present invention relates to an improved process for the preparation of valacyclovir or salt thereof.

The present invention provides a novel polymorphic Form "W-lll" of atorvastatin calcium and hydrates thereof and process for its preparation. The invention further relates to pharmaceutical compositions comprising Form "W-lll" of atorvastatin calcium and hydrates thereof and one or more pharmaceutically acceptable c...

The present invention provides a novel polymorphic Form "W-l" of atorvastatin calcium and hydrates thereof and process for its preparation. The invention further relates to pharmaceutical compositions comprising Form "W-l" of atorvastatin calcium and hydrates thereof and one or more pharmaceutically acceptable carri...

The present invention provides a stable aqueous liquid formulation suitable for ophthalmic administration, comprising gatifloxacin and polyethoxylated castor oil.

The present invention relates to extended release pharmaceutical composition comprising Phenytoin or salt thereof, disintegrant and rate controlling material. The pharmaceutical composition of the present invention is prepared by wet granulating the blend of phenytoin sodium, disintegrant and rate controlling materi...

The present invention relates to an improved process for the preparation of 1-cyclopropyl-6-fluoro-8-methyl-7-(4-amino-3,3-dimethyl-piperidin-1-yl)-4-oxo-1,4-dihydro-quinolin-3-carboxylic acid hydrochloride salt and optically pure enantiomers thereof.

The present invention provides a novel polymorphic Form "W-ll" of atorvastatin calcium and hydrates thereof and process for its preparation. The invention further relates to pharmaceutical compositions comprising Form "W-ll" of atorvastatin calcium and hydrates thereof and one or more pharmaceutically acceptable car...

The present invention provides a pharmaceutical composition, wherein the composition comprises of more than 40% of 8-{4-[2(S)-Amino-propionyloxy] piperidine-1-yl}-9-fluoro-5 (S)-methyl-6, 7-dihydro-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid or pharmaceutically acceptable salts, esters or products thereof i...

A process for the preparation 1,2-benzisoxazole-3-acetic acid, wherein the said process comprises of a) hydroxylamine hydrochloride added with sodium methoxide and 4-hydroxy coumarin, b) heating of the reaction mass and removal of solvent, c) extraction of reaction mass with toluene at pH 8-10 in presence of aqueous...

The present invention a process for the preparation of chloroethanol adduct intermediate of formula II useful in preparation of cetirizine or salt thereof, wherein the said process comprises of a) reacting 4-chlorobenzhydryl piperazine with 2-chloroethanol using organic solvent in presence of a base b) isolating the...

The present invention encompasses 7-(substituted indole)hept-6-enoic acid and salts thereof. The present invention further provides pure fluvastatin and salts thereof.

The present invention provides a process for purification of epinastine hydrochloride. The present invention further provides pure epinastine hydrochloride.

The present invention provides a process for the preparation of donepezil hydrochloride. Further the process of present invention provides donepezil hydrochloride substantially free of 2-((1-benzylpiperidin-4-yl)methylene)-2,3-dihydro-5,6-dimethoxyinden-1 -one hydrochloride.

The present invention provides a novel polymorphic Form 'W-VII' of atorvastatin calcium and hydrates thereof and process for its preparation. The invention further relates to pharmaceutical compositions comprising Form 'W-VII' of atorvastatin calcium and hydrates thereof and one or more pharmaceutically acceptable c...

The present invention provides a process for the purification of donepezil hydrochloride.

The present invention provides an improved process for the preparation of epinastine hydrochloride.

The present invention provides a novel polymorphic Form "W-VI" of atorvastatin calcium and hydrates thereof and process for its preparation. The invention further relates to pharmaceutical compositions comprising Form "W-VI" of atorvastatin calcium and hydrates thereof and one or more pharmaceutically acceptable car...

The present invention provides a novel polymorphic form 'W-XII' of atorvastatin sodium and hydrates thereof and process for its preparation. The invention further relates to pharmaceutical compositions comprising form 'W-XII' of atorvastatin sodium and hydrates thereof and one or more pharmaceutically acceptable car...

The present invention provides stabilized pharmaceutical composition comprising bupropion or salt thereof and stabilizing agent along with other pharmaceutically acceptable excipients wherein the said stabilizing agent is selected from a group of esters.

The  present  invention  provides  a  pharmaceutical  composition  comprising clopidogrel hydrochloride and glyceryl behenate that is bioequivalent to the commercially available Plavix® tablet.

The present invention provides an improved process for preparation of anastrozole wherein the said process comprises of, a) reacting α, α, α’, α’-tetramethyl-5-bromomethyl-1,3-benzenediacetonitrile with sodium 1,2,4-triazole, b) isolating the anastrozole from the reacting mass thereof.

The present invention relates to an efficient one-pot process for preparation of anhydrous zoledronic acid, wherein the said process comprises of a) reacting imidazol-1-yl acetic acid or salt thereof with phosphorous acid and phosphorous oxychloride b) to the mixture of step a) organic solvent is added c) isolating...

The present invention relates to A pharmaceutical composition of valacyclovir or salt thereof wherein the said composition comprises granules of valacyclovir or salt thereof in admixture with pharmaceutically acceptable excipients prepared by using a mixture of aqueous and non-aqueous vehicle.

A process for preparation of clarithromycin wherein said process includes the steps of, a) adding methylating agent to protected oxime of formula-II in tertiary solvent to get compound of Formula III, b) converting compound of formula III to clarithromycin. c) isolating the clarithromycin the reaction mixture thereo...

The present invention provides a pharmaceutical solid dosage form for oral administration comprising triple combination of mecobalamin, pyridoxine or salt thereof and folic acid along with other pharmaceutically acceptable carriers wherein the mecobalamin is present in an extended release form. ...

The present invention relates to a new and efficient process for the manufacture of L-Threonine-O-(1,1-dimethylethyl) ester; [H-Thr-(tBu)-O-tBu] of Formula (I). The compound of Formula (I) is a key product for the manufacture of human insulin from porcine or bovine insulin.

The present invention provides a stable silicone oil-in-water emulsion substantially free of any additives. The emulsions of the invention can be stable for at least about fifteen (15) and preferably for at least about thirty (30) minutes. The emulsions of the invention are useful for the siliconization of glass con...

The present invention relates to a delayed release dosage form comprising of a core containing pantoprazole or salt thereof in admixture with pre-gelatinized starch as binder, filler and optionally other pharmaceutically acceptable excipient and an inorganic base, an inert water-soluble intermediate layer surroundin...

The present invention provides a solid oral dosage formulation comprising ramipril or salt thereof, at least one pharmaceutically accepted excipient, and a buffering agent.

A process for preparation of venlafaxine or salt thereof wherein the said process comprises of a) heating amino intermediate of Formula 3 with formic acid and a source of formaldehyde in presence of water for 6 hours or more at a temperature of 80°C and above, b) isolating venlafaxine or salt thereof from the reacti...

The present invention provides a pharmaceutical composition comprising repaglinide or salt thereof along with pharmaceutically acceptable excipients, wherein repaglinide has a particle size D90 of less than or equal to 50 microns.

The present invention provides topical composition comprising of ketotifen or salt thereof along with cyclodextrins or derivatives thereof and other pharmaceutically acceptable carriers.

The invention provides process for preparation of 5-(acetylamino)-N,N"-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzendicarboxamide from 5-Amino-N,N’bis(2,3-dihydroxyproyl)- ispohthalamide where acetyl chloride is used as a acetylating agent and N-Methyl pyrrolidone is used as a catalyst. Reaction carried out with...

The invention provides efficient process for preparation of 5-chloroacetamido-N, N"- bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide from 5-Amino-N,N’bis(2,3-dihydroxyproyl)-2,4,6-triiodo-1,3-benzenedicarboxamide.

The present invention relates to a controlled release diltiazem pharmaceutical composition comprising a) delayed release pellets comprising diltiazem or salts thereof along with pharmaceutically acceptable excipients and b) rapid release minitablets.

The present invention relates to a controlled release diltiazem pharmaceutical composition comprising a) delayed release pellets comprising diltiazem or salts thereof along with pharmaceutically acceptable excipients and b) rapid release minitablets.

The invention provides industrial process for preparation of loversol from 5-hydroxyacetamido-N,N’-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide. The invention further provides the process in which reaction proceeds faster and products obtained is having better purity.

The present invention relates to 2-bromo-4-aminocyclohexanone, and to their application in the synthesis of pramipexole or salt thereof. Pramipexole of Formula I, is chemically (S)-2-amino-4,5,6,7-tetra-hydro-6-(propylamino)benzothiazole and is indicated for the treatment of the signs and symptoms of idiopathic Park...

The present invention provides a novel polymorphic Form C of anhydrous pramipexole dihydrochioride. The invention also relates to pharmaceutical compositions that include the anhydrous pramipexole dihydrochioride and one or more pharmaceutically acceptable carriers, excipients or diluents. Pramipexole of Formula I i...

The present invention provides an extended release dosage form of metoprolol or salt thereof comprising an inert core coated with a solution or suspension of metoprolol or salt thereof in admixture with a binder and a solvent. The drug layer is further coated with one or more release-controlling layer(s). ...

The present invention relates to a process for preparation of Fluvastatin or salt thereof wherein the said process comprises of a. drying fluvastatin sodium containing organic solvent or solvents at a temperature of 40° C and above, b. intermittently sieving, sizing and reshuffling the particle bed, c. isolating flu...

The present invention provides modified a pharmaceutical composition comprising of triple combination of rabeprazole sodium, aceclofenac and paracetamol wherein release of rabeprazole from the said composition is independent of the release of aceclofenac and paracetamol characterized by the fact that, at least 50% o...

The present invention relates to a solid dosage form oral administration comprising: (a) an enteric coated tablet comprising of rabeprazole sodium with an inert intermediate layer surrounding the core followed by enteric coating over the said intermediate layer and (b)granules comprising of aceclofenac and paracet...

The present invention provides a tablet in tablet dosage form for oral administration comprising: a) an inner tablet comprising of inert intermediate layer surrounding the core comprising of therapeutically effective amount of rabeprazole sodium and the inert intermediate layer is further coated with enteric coating...

The present invention provides a solid dosage form in the form of enteric coated microtablets for oral administration comprising tamsulosin or salt thereof along with pharmaceutically acceptable excipients wherein the said microtablets are free of an intermediate layer or seal coat between the drug core and the ente...

The present invention provides a pharmaceutical composition comprising 25-200 mg of diclofenac potassium in an extended release form and 5-20 mg of meloxicam in an immediate release form in admixture with pharmaceutically acceptable carrier.

ABSTRACT The present invention relates to sustained release solid pharmaceutical composition comprising antihypertensives, in particular, Metoprolol succinate or its pharmaceutically acceptable derivatives thereof and a process for preparing such a formulation. The present invention is a composition comprising Meto...

The present invention of a process for preparation of ioversol. The process includes steps of, a) reacting N,N’-bis(2,3-dihydroxypropy)-5-(2-chloroacetamido)-2,4,6-triiodoisophthalamide with alkylating agent in absence of base, b) converting the product of step a) to ioversol.

The present invention provides a pharmaceutical composition comprising clopidogrel or monobasic acid salts thereof and one or more hydrated excipients optionally along with suitable lubricant.

A present invention of 1. A process for the preparation of 1-[cyano-(4-methoxyphenyl) methyl] cyclohexanol, an useful intermediate for the preparation of venlafaxine or salt thereof. The process includes step of : a) reacting p-methoxyphenylacetonitrile with cyclohexanone in presence of water b) isolating 1-[cyano-...

The present invention pertains to a triple drug combination composition for the treatment of pain by producing a synergistic effect.The composition comprises of tramadol,acetaminophen and ibuprofen all of which exert analgesic by different mechanisms of action.Tramadol is a centrally acting analgesic agent,ibupr...

The present invention provides a pharmaceutical composition comprising granules of paroxetine or salt thereof along with hydroxypropyl alkylcellulose and hydroxyalkyl cellulose and one or more pharmaceutically acceptable excipients, wherein the granules of paroxetine or salt thereof are coated with pharmaceutically ...

The present invention provides a pharmaceutical composition comprising losartan or pharmaceutical acceptable salts thereof wherein the said composition can be prepared by dry granulation method, when particle size of losartan is less than about 30µm and by direct compression method when particle size of losartan is ...

The present invention relates to a process for the preparation of a compound of formula II, an intermediate useful in the synthesis of irbesartan. The process includes the steps of a) condensing a compound of formula III, with a compound of formula IV, in the presence of polar aportic solvent and powder potassium h...

The present invention of a pharmaceutical composition comprising fexofenadine of salts thereof and peseudoephedrine or salt thereof along with pharmaceutically acceptable excipients wherein the said composition of prepared by dry granulation method.

The present invention provides a pharmaceutical composition of modafinil or pharmaceutical^ acceptable salts thereof comprising mixture of micronized and unmicronized modafinil particles, sodium starch glycolate in admixture with one or more pharmaceutically acceptable excipients.

The present invention provides apharmaceutical composition comprising paroxetine or salt thereof along with hydroxypropyl alkylcellulose and hydroxyalkyl cellulose and one or more pharmaceutically acceptable excipients.

The present invention provides a bilayer tablet comprising modafinil or pharmaceutical^ acceptable salts thereof wherein the tablet comprises micronized and unmicronized modafinil particles. Modafinil is a wakefulness-promoting agent indicated to improve wakefulness in patients with excessive sleepiness associated w...

The present invention provides a pharmaceutical composition comprising a centrally acting opioid analgesic agent and a peripherally acting non-opioid analgesic agent. The compositions of the present invention provide improved analgesia when compared to the individual agents taken alone. The compositions of the inven...

The present invention provides a pharmaceutical composition, which comprises of galantamine or salt thereof along with microcrystalline cellulose and other pharmaceutically acceptable excipients wherein the formulation is characterized in that solubilizer is "substantially absent" in the formulation. ...

The present invention provides a stabilized injectable pharmaceutical composition of docetaxel, which comprises of docetaxel, surfactant and ethanol, wherein the pH of the injectable is adjusted between 3 and 6 using a suitable acid.

The present invention provides a stabilized pharmaceutical composition for the parenteral administration comprising Lorazepam or pharmaceutically acceptable salts thereof wherein the composition comprises sparged/purged carbon dioxide that imparts better stability and significant reduction in the impurity level as c...

A unit dose pharmaceutical composition containing comprising 1gm levetiracetam or salt thereof wherein the composition comprises of not more than 86% by weight of levetiracetam along with pharmaceutically acceptable excipients.

The present invention provides a novel sustained release pharmaceutical composition of bupropion or salts thereof with improved stability wherein the composition comprises of granules of bupropion prepared by non-aqueous granulation method. The granules are mixed with a rate-controlling polymer along with other phar...

The present invention provides a process for the preparation of azithromycin, wherein the process comprises of a) reducing compound of Formula-ll with suitable boron reducing agent, b) extracting the boron complex of compound of Formula III from the reaction mass, c) N-methylating the boron complex of compound of F...

In one of the aspect of the present invention there is provided a new polymorphic form W-1 of valacyclovir hydrochloride, wherein the said polymorph is stable, consistently reproducible and is used to make pharmaceutical compositions. The XRD of the polymorph W-1 showed 20 values of major peak intensity at 3.64, 7.2...

The present invention provides a process for the preparation of bethanechol or salt thereof, wherein the said process comprises of a) reacting 2-hydroxy propyl trimethyl ammonium halide with triphosgene solution, b) isolating the bethanechol chloride from reaction mass thereof.

The present invention provides pharmaceutical formulation of oxcarbazepine or pharmaceutical^ acceptable salt thereof as the active pharmaceutical ingredient along with pharmaceutically acceptable excipients for oral administration.

The present invention provides a novel polymorphic Form W-1 of olanzapine and a process for the preparation thereof.

The present invention relates to aprocess for the preparation of 3,5-bis (2-cyanoprop-2-yl) toluene intermediate, useful in the preparation of anastrozole. The process comprising: a) reacting 3,5-bis (cyanomethyl) toluene with dimethyl sulfate in presence of alkali metal base, b) isolating 3,5-bis (2-cyanoprop-2-yl)...

The present invention provides a novel polymorphic form of venlafaxine hydrochloride and a process for the preparation thereof. Venlafaxine hydrochloride of the formula I is chemically known as (±)-1-[a-[(dimethylamino) methyl]-p-methoxybenzyl] cyclohexanol. Venlafaxine is indicated in the treatment of major depress...

The present invention provides a stable topical composition comprising at least one pharmaceutically acceptable active agent along with hyaluronate lyase, wherein hyaluronate lyase is stabilized in the said composition by immobilization. The invention relates to an agent for treating, prophylaxis and/or metaphylaxis...

The present invention provides a pharmaceutical composition of fenofibrate or salt thereof comprising non-micronized fenofibrate, polyethylene glycol or derivative thereof and sorbitol in admixture with one or more pharmaceutically acceptable excipients. The present invention also provides a process of preparing the...

The present invention provides pharmaceutical composition of fenofibrate or salts thereof comprising non-micronized fenofibrate, Polyethylene glycol or derivative thereof, and one or more surfactants. The present invention also provides a process of preparing pharmaceutical composition of fenofibrate or salts thereo...

The present invention provides a process for reducing residual alcohol content in solid valacyclovir hydrochloride. The invention further provides a valacyclovir hydrochloride having less than 1000 ppm of ethanol.

The present invention relates to stable solutions suitable for ophthalmic, otic, or nasal administration that include nadifloxacin and pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of the stable solutions.

The present invention provides a novel polymorphic Form "W-V of atorvastatin calcium and hydrates thereof and process for its preparation. The invention further relates to pharmaceutical compositions comprising Form "W-V of atorvastatin calcium and hydrates thereof and one or more pharmaceutically acceptable carrier...

The present invention provides a novel polymorphic Form "W of atorvastatin calcium and hydrates thereof and process for its preparation. The invention further relates to pharmaceutical compositions comprising Form "W of atorvastatin calcium and hydrates thereof and one or more pharmaceutically acceptable carriers, e...

The  present  invention  provides  a  process for  preparation  of epinastine hydrobromide.

The present invention relates to an improved process for purification of 1-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine, an useful ranolazine intermediate.

The invention provides 1-(2-substitutedamino-1-oxopropyl)octahydro cyclopenta [b] pyrrole-2-carboxylic acid or salts thereof having the structure of formula-II and process of preparation of the same. The invention further provides a pharmaceutical composition comprising 1-(2-substitutedamino-1-oxopropyl) octahydrocy...

The present invention relates to a process for preparation of ranolazine free base. The invention further provides Ranolazine free base having purity 98% or more.

The invention provides a process for the preparation of eszopiclone salts.

The present invention relates to a process for the preparation of 1-(2-methoxyphenoxy)2,3-epoxypropane as a ranolazine intermediate in presence of phase transfer catalyst and in biphasic solvent at controlled temperature.

The invention provides substituted-2-amino-1H-purin-6-ones and salts thereof and process of preparation of the same. The invention further provides a pharmaceutical composition comprising substituted-2-amino-1H-purin-6-ones and salts thereof. In yet another aspect of the invention there is provided pharmaceutical co...

The invention provides process for preparation of pure valacyclovir hydrochloride. The invention further provides pure valacyclovir and salts thereof having 2-amino-9-(methoxymethyl)-1H-purin-6(9H)-one content of 1% or less. The invention also provides a pharmaceutical composition of valacyclovir or salts thereof ha...

The present invention relates to novel poultry and livestock supplements that effectively replace the use of antibiotics in poultry and livestock feeds, that comprise probiotics and methylsulfonylmethane. The supplements further comprise saccharides, vitamins, carotenoids, xanthophylls, minerals and electrolytes. Th...

The present invention provides a novel polymorphic Form "W-X" of atorvastatin calcium and hydrates thereof and process for its preparation. The invention further relates to pharmaceutical compositions comprising Form "W-X" of atorvastatin calcium and hydrates thereof and one or more pharmaceutically acceptable carri...

The invention provides an industrial process for the preparation of eszopiclone. The invention further provides pure eszopiclone base having chiral purity of 99.0% or more and residual solvent below 0.5%.

The present invention provides a process for the preparation of iodinated X-ray contrast agent, lohexol. More particularly this invention provides a industrial process for the preparation of 5-Acetylamino-N,N'-Bis(2,3-dihydroxypropyl) - 2,4,6-Triiodoisophthalamide intermediate. Chemically, lohexol is 5-[Acetyl(2,3-d...

The present invention provides a process for preparation of anhydrous amorphous azithromycin. The present invention further provides a process for converting crystalline anhydrous azithromycin to amorphous anhydrous azithromycin.

The present invention provides novel polymorphic form 'W-IV of anhydrous crystalline azithromycin. A/-methyl-11-aza-10-deoxo-10-dihydroerythromycin A, known by its generic name Azithromycin of Formula I, is a broad-spectrum semi-synthetic macrolide antibiotic compound belonging to the erythromycin A family. ...

The present invention provides novel polymorphic form 'W-V of anhydrous crystalline azithromycin. More particularly the present invention provides acetonitrile solvate of anhydrous crystalline azithromycin referred as polymorphic form 'W-V. A/-methyl-11-aza-10-deoxo-10-dihydroerythromycin A, known by its generic na...

The present invention provides a controlled release pharmaceutical composition comprising an erythromycin derivative or salts thereof, a combination of one or more hydrophilic polymers.

The present invention provides a novel polymorphic Form "W" of olanzapine and a process for the preparation thereof.

The present invention provides a novel polymorphic Form "W-IV of atorvastatin calcium and hydrates thereof and process for its preparation. The invention further relates to pharmaceutical compositions comprising Form "W-IV of atorvastatin calcium and hydrates thereof and one or more pharmaceutically acceptable carri...

The invention provides an improved process for the preparation eszopiclone.

The invention provides 2-[[3,4-dimethoxy-2-pyridinyl) methyl]sulfinyl]-substituted benzimidazoles and salts thereof and process for isolation of the same. The invention further provides a pharmaceutical composition comprising 2-[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-substituted benzimidazoles and salts thereof...

The invention relates to a sustained release formulation, which comprises of a)first layer comprising alfuzosin or salt thereof and 0.1 to 95% of at least one hydrophobic rate controlling polymer, b)second layer comprising alfuzosin or salt thereof and 0.1 to 95% of at least one rate controlling polymer, c)an opt...

The present invention provides a stable solid oral dosage formulation comprising of ramipril and its salt thereof, wherein ramipril is mixed with at least one pharmaceutically accepted excipient, which is pre-coated with gelatin.

The present invention provides a delayed release dosage form comprising of a core containing pantoprazole or salt thereof in admixture with binder, filler and, optionally, other pharmaceutically acceptable excipient and an inorganic base, an inert water-soluble intermediate layer surrounding the core and an outer en...

The present invention relates to a dosage form wherein the dosage form comprises of a comprising of pharmaceutically active ingredient and pharmaceutically acceptable excipient or an inert core coated with pharmaceutically acceptable excipient which is then optionally coated with pharmaceutically acceptable release ...

The present invention relates to an extended release solid pharmaceutical composition comprising two layers wherein the first layer comprises of a) a therapeutically effective amount of clarithromycin or a pharmaceutically acceptable salt, solvate or derivatives thereof along with at least one rate controlling hydro...

The present invention provides to a pharmaceutical dosage form comprising 2 g of cefepime in combination with 0.1-4 g of sulbactam along with optional pharmaceutically acceptable excipient.

The present invention provides a process for preparation of crystalline cefdinir having XRD pattern as depicted in Figure 1 wherein the said process comprises of a) dissolving imidazole salt intermediate of formula II in a suitable solvent, b) acidifying the solution under cooling, c) isolating crystalline cefdinir ...

The present invention provides a process for the preparation of Pramipexole or salt thereof wherein the said process comprises of, a) reacting the compound of Formula V or salt thereof with propylating agent to get compound of Formula VI salt thereof b) oxidizing the compound of formula VI to get compound of formula...

The present invention provides a solid dosage form for oral administration comprising: c) a controlled release core comprising metformin or pharmaceutically acceptable salt thereof along with pharmaceutically acceptable excipient; d) an immediate release layer comprising rosiglitazone or pharmaceutically acceptable ...

The present invention provides a pharmaceutical composition of quetiapine or salt thereof without a binder wherein the composition comprises of quetiapine or salt thereof as an active ingredient in admixture with filler, lubricant, disintegrant and optionally other pharmaceutically acceptable carrier. ...

The present invention relates to a controlled release dosage form comprising glipizide or salt thereof wherein the glipizide is present in the form of complex with cyclodextrins or derivatives thereof along with pharmaceutically acceptable excipients.

The present invention provides a melt granulation process for preparing a pharmaceutical composition of clopidogrel or salt thereof optionally containing suitable excipients wherein the process comprises of granulating the clopidogrel or salt thereof with PEG under heating followed by blending the granules with othe...

The present invention provides a method of treating moderate to severe pain by administering to a subject in need thereof, a pharmaceutical composition comprising 25-400 mg of tramadol or a pharmaceutically acceptable salt or derivative thereof and 25-200 mg of diclofenac or a pharmaceutically acceptable salt or der...

A pharmaceutical composition, which comprises of galantamine or salt thereof along with sugar alcohols and other pharmaceutically acceptable excipients.Galantamine hydrobromide and microcrystalline cellulose are sifted and mixed in non-shear blender. Mannitol, colloidal silicon dioxide, talc, crospovidone are sifted...

The present invention provides formulation of oxcarbazepine or pharmaceutically acceptable salt thereof, cyclodextrin or derivative thereof along with pharmaceutically acceptable excipients. A solid dosage form comprising oxcarbazepine or pharmaceutically acceptable salt thereof wherein oxcarbazepine is present in a...

The present invention provides a process for preparation of polymorphic mixture of desloratadine. More particularly present invention provides a process for preparation of a mixture of a crystalline desloratadine Form I which contains Form II in specific range 15 - 30%.

The present invention provides an aqueous pharmaceutical dosage form comprising therapeutically effective amount of oxcarbazepine or salt thereof and cyclodextrins or derivatives thereof along with pharmaceutically acceptable excipients.

The present invention provides pharmaceutical formulation of oxcarbazepine or pharmaceutically acceptable salt thereof along with pharmaceutically acceptable excipients and a process for preparing the same.

A process for purification of valacyclovir hydrochloride wherein the said process comprises of, a) dissolving valacyclovir hydrochloride in water b) adding a mixture of two or more solvent comprises of an alkanol organic solvent wherein one organic and other is selected from group comprising of tetrahydrofuran, acet...

The present invention provides an improved process for the preparation of imine intermediate useful in preparation of pioglitazone or salt thereof. A process for the preparation of imine intermediate useful in preparation of pioglitazone or salt thereof, wherein the said process comprises of a) reacting compound of ...

The present invention provides a topical composition comprising of epinastine or salt thereof along with cyclodextrins or derivatives thereof and other pharmaceutically acceptable carriers.

The present invention provides a pharmaceutical composition, which comprises of granules of repaglinide or salt thereof along with pharmaceutical acceptable excipients, wherein the granules of repaglinide or salt thereof along with other pharmaceutical acceptable excipients are prepared by dry granulation method. ...

There is provided a press-coated tablet, comprising of a core comprising one or more active substances and optionally along with one or more pharmaceutically acceptable excipients, and a coating surrounding the said core, wherein the said core is being disposed within said coating such that the coating thickness ...

This invention relates to a compliance blister package comprising a matrix of blisters arranged in a plurality of columns and plurality of rows which comprises a combination of one of the fixed dose combination dosage form comprising two or more therapeutically active ingredients loaded into blisters of one of the c...

There is provided a programmed release press-coated tablet, comprising of a core comprising one or more corticosteroid and optionally along with one or more pharmaceutically acceptable excipients, and a coating surrounding the said core comprising one or more inorganic salts of calcium ions coprocessed with glyceryl...

The present invention provides a stabilized pharmaceutical composition comprising fluvastatin or salts thereof, wherein the fluvastatin is coated with a pharmaceutically acceptable polymer. The polymer coated fluvastatin is mixed with pharmaceutically acceptable excipients.

The present invention provides a solid dosage from for oral administration comprising: c) an inner comprising a proton pump inhibitor with an inert intermediate layer surrounding the core followed by enteric coating over the said intermediate layer and d) outer core comprising of granules of antipyretic-analgsic and...

The present invention provides a method of treating discomfort and mild to severe pain wherein the method comprise of administering to a patient in need thereof, a pharmaceutical composition comprising a combination of acetaminophen or a pharmaceutically acceptable salt or derivative thereof and codeine or a pharmac...

The present invention provides an ophthalmic composition comprising naphazoline or salt thereof along with ophthalmically acceptable carrier component, characterised by the fact that the polyanionic component is substantially absent from the composition.